301015 百洋医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入5,218,119-7.27%7,506,5158,094,4588,255,9987,509,618
减:营业总成本4,753,803-4.24%6,840,2487,169,3377,256,7826,832,016
    其中:营业成本3,179,991-9.75%4,693,7295,220,6605,507,1525,424,874
               财务费用88,19912.53%107,63171,10965,61348,385
               资产减值损失(13,612)-66.81%(47,107)(16,023)1,911(1,160)
公允价值变动收益(25,297)-134.13%73,3561,716616(10,750)
投资收益(35,350)474.33%19,59759,20944,5911,877
    其中:对联营企业和合营企业的投资收益(33,871)668.24%7,19351,12118,87415,601
营业利润392,496-44.44%736,266977,7381,043,604674,258
利润总额390,091-43.90%722,975966,6281,027,991668,550
减:所得税费用78,985-41.35%151,046199,597257,263178,709
净利润311,106-44.51%571,929767,031770,728489,841
减:非控股权益71,517-15.05%97,24475,43758,667(16,757)
股东净利润239,590-49.71%474,685691,593712,061506,598

市场价值指针
每股收益 (元) *0.460-49.45%0.9001.3201.3600.960
每股派息 (元) *----0.5710.7620.7620.762
每股净资产 (元) *4.420-2.45%4.4964.3294.8874.384
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容